Retractions are on the rise. But reams of flawed research papers persist in the scientific literature. Is it time to change the way papers are published?
April 12, 2016|
Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.